Member Info for Shukan

Progress in #Science is rarely linear or gradual. There are moments that change the #World #Eureka

Dr Sandler earlier this morning

Obviously

What is happening?
Exercise of Warrants - Final Opportunity
Expiration date: 5th October 2019 Exercise ratio: 1-for-1 Exercise price: GBP0.04 Pay date: upon receipt
Option 1: Warrants to Lapse (Default) Option 2: Warrants to Exercise The default option will apply to all holders whose instructions are not received by the deadline.
Warrant holders in Hemogenyx Pharmaceuticals have the final opportunity to exercise each warrant at a price of GBP0.04 to receive 1 Ordinary Share in Hemogenyx Pharmaceuticals.
Please ensure you have cleared funds in your account by our deadline date. Holders who exercise such warrants will receive the new shares on upon receipt of the stock from the company.
Holders who do not exercise before the above deadline will have no further chances to do so and it is expected the warrants will be deemed worthless.

not in this space - very limited capture maket

Nigel said the very same thing with their viagra reformulation- 2.5p prediction looking good

Last Quarter of the year we should be concluded on deals with multi Billion dollar Pharma- and they sell at 2.3 pence - the smart load up increased holding to over 2.1 million shares - if this micro company with stem cell therapies to eliminate two forms of blood cancer in over thirty percent of patients is not a take over target I don’t know what is - onboard Nasdaq Pharma- ORGS -J&J - Lake Pharma- and one “unknown” Pharma huge opportunity here - warrants clear October- then BOOM

****************************/articles/riverfort-global-opportunities-vadim-alexandre-on-hemogenyx-and-chris-bailey-a54db6a/

Incoming

And the idiots sell at 2.3p

Hemogenyx operates in an area of intense focus for industry. Therefore, we compiled a peer group of ex-UK development-stage companies which operate within similar treatment areas to Hemogenyx (i.e. treatment of blood cancers or alternate therapies for bone marrow transplants). The median-market capitalisation of the peer-group is £129.1m, over 10-fold higher than that of Hemogenyx (Table 1).
We then compared Hemogenyx to several AIM or LSE standard-listed drug developers at a preclinical stage (Table 2). As is demonstrated, Hemogenyx’s current market capitalisation is half that of the peer-group median of c.£17.2m. Given that the Company has multiple assets, each with collaboration agreements, we believe that this price discrepancy is unjustified and that Hemogenyx shares consequently have considerable upside potential.
Finally, we note that the two investments by Orgenesis into the Immugenyx and Hemogenyx-Cell subsidiaries are on pre-money valuations of US$8m and US$12m respectively. The combined value of these two subsidiaries is c.20% higher than the current market capitalisation of Hemogenyx. Note this US$20m valuation does not include the CDX Ab platform, the Group’s leading technology, over which Hemogenyx is in advanced discussions with a potential partner.
We feel these points highlight the undervalued nature of this stock.

In May 2018, Hemogenyx struck a development agreement with an unnamed multinational biopharmaceutical company regarding its CDX antibody (CDX Ab), the Group’s lead asset. The partner has initiated preliminary discussions regarding a potential licensing deal. If the partner chooses to in-license the CDX Ab product candidate, we expect the partner would finance and manage the development of the platform through clinical trials, which would significantly reduce the capital required for commercialisation.

https://www.uploadlibrary.com/Liam.GascoigneCohen/SP_Angel_Hemogenyx_Initiation_Note_Final_29082019.pdf

Added - just waited for the impatient- pays dividends thank you.

INDEED:

2.5p it’s going to be a long wait - risky

yep that's my target

come on where are you? I need to hoover up cheap shares

7.47 to sell

looks like that clown DAVEVT sold out £1.51 sell

I spoke with Peter Redmond two weeks ago - "irons in the fire" was the conversation.